[Intraocular bevacizumab as palliative therapy in melanoma-metastasis-associated rubeotic secondary glaucoma].
Jaissle
G B
GB
Universitäts-Augenklinik, Department für Augenheilkunde,Eberhard-Karls-Universität Tübingen, Tübingen. gesine.jaissle@googlemail.com
Ulmer
A
A
Henke-Fahle
S
S
Aisenbrey
S
S
Fierlbeck
G
G
Bartz-Schmidt
K U
KU
Szurman
P
P
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005134:Eye Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D005901:Glaucoma / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D010166:Palliative Care / Q000379:methods; D012878:Skin Neoplasms / Q000473:pathology; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab